Korean J Ophthalmol > Volume 40(5); 2026 > Article
Seong and Huh: Surgical Outcomes of A-Stream Shunt Implantation in Neovascular Glaucoma: A Single-Center Retrospective Cohort Study

Abstract

Purpose

To evaluate 6-month surgical outcomes of A-stream shunt implantation in eyes with neovascular glaucoma (NVG) and to describe postoperative ripcord management patterns.

Methods

This retrospective, single-center cohort study included consecutive NVG eyes that underwent A-stream shunt implantation between August 2024 and April 2025 with available follow-up through 6 months. Intraocular pressure (IOP) and the number of glaucoma medications were assessed at postoperative day 1, week 1, weeks 2-3, and months 1, 2, 3, and 6. Complete success was defined as IOP 6 to 18 mmHg with ≥20% reduction from preoperative decision IOP, without glaucoma medications or additional glaucoma surgery. Qualified success was defined using the same IOP and reduction criteria with or without medications, and without additional glaucoma surgery. Ripcord removal timing and postoperative interventions were recorded.

Results

Thirty-five eyes were included. Mean preoperative IOP was 37.0 ± 13.2 mmHg on 2.6 ± 1.2 medications. Mean IOP decreased to 10.1 ± 6.9 mmHg on postoperative day 1 and remained in the mid-teens through 6 months (15.7 ± 6.3 mmHg). Medication burden was markedly reduced postoperatively and remained low at 6 months (0.7 ± 0.9). Ripcord removal was performed in 28 eyes (80.0%); mean time to removal was 6.6 ± 4.7 weeks, and 14 eyes (40.0%) underwent removal within 4 weeks. Mean IOP at ripcord removal was 21.2 ± 5.4 mmHg. At 6 months, complete and qualified success rates were 57.1% and 85.7%, respectively. Bleb needling and 5-fluorouracil injections were performed in 14.3% and 25.7% of eyes, respectively; one eye (2.9%) required reoperation.

Conclusions

A-stream implantation provided substantial short-term IOP reduction with low medication requirements and favorable qualified success through 6 months in NVG. Ripcord removal was frequently required and often performed early, supporting stepwise outflow titration as a practical postoperative strategy.

Neovascular glaucoma (NVG) is a severe secondary glaucoma characterized by anterior segment neovascularization and progressive angle closure driven by ocular ischemia [1-3]. Despite advances in retinal ischemia control with panretinal photocoagulation (PRP) and intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, NVG often presents with markedly elevated intraocular pressure (IOP) and rapid optic nerve damage, frequently requiring surgical intervention to achieve adequate IOP control [4,5].
Filtering surgery such as trabeculectomy has been widely used; however, outcomes in NVG can be compromised by postoperative inflammation, hyphema, and aggressive subconjunctival fibrosis, leading to higher rates of bleb failure and complications [6]. Consequently, glaucoma drainage devices, including valved and nonvalved implants, have become a mainstay for refractory NVG. Prior studies of Ahmed glaucoma valve (AGV) implantation in NVG reported favorable short-term IOP reduction and qualified success rates, although additional interventions and long-term durability remain concerns [7,8].
The A-stream glaucoma shunt is a recently introduced drainage device designed to facilitate controlled aqueous outflow and stepwise postoperative IOP adjustment using an intraluminal ripcord. In a recent 6-month study, A-stream implantation demonstrated meaningful IOP lowering, a practical strategy for staged IOP control through ripcord removal, and an acceptable safety profile in a mixed glaucoma population [9]. However, evidence regarding the outcomes of A-stream implantation specifically in NVG remains limited, and NVG-associated factors—such as recurrent hyphema, fibrin reaction, and active neovascularization— may adversely influence the postoperative course and surgical success.
Therefore, we conducted a single-center retrospective cohort study to evaluate the short-term surgical outcomes of A-stream shunt implantation in eyes with NVG. We assessed postoperative IOP and medication burden, time-dependent complete and qualified success rates, ripcord removal timing, postoperative interventions (e.g., bleb needling and 5-fluorouracil injections), and the incidence of additional glaucoma surgery and complications through 6 months of follow-up.

MATERIALS AND METHODS

Ethics statement

The study adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of Yeungnam University Medical Center (No. 2026-01-019), with a waiver of informed consent due to the use of deidentified data and the retrospective nature of the study.

Study design and participants

This retrospective, single-center cohort study included consecutive eyes with NVG that underwent A-stream shunt implantation at Yeungnam University Medical Center between August 2024 and April 2025. NVG was diagnosed based on iris and/or angle neovascularization associated with elevated IOP in the setting of an ischemic retinal disorder. A-stream implantation was considered when IOP exceeded the target level or glaucoma progression was suspected despite maximally tolerated medical therapy, along with standard management of retinal ischemia (e.g., PRP and/or intravitreal anti-VEGF therapy) at the treating physician’s discretion. When feasible, A-stream implantation was performed after stabilization of iris/angle neovascularization with PRP and/or intravitreal anti-VEGF therapy. Eyes were included if they had at least 6 months of postoperative follow-up (or sufficient documentation at predefined visits through 6 months). Eyes with insufficient clinical documentation of key outcomes (preoperative decision IOP and postoperative IOP at prespecified visits) or with a primary diagnosis other than NVG were excluded.

Surgical technique

All surgeries were performed by a glaucoma specialist under retrobulbar/sub-Tenon anesthesia. A fornix-based conjunctival flap was created in the superior quadrant. Mitomycin C (0.04%)-soaked sponges were applied for 2 to 3 minutes, followed by copious irrigation. A partial-thickness scleral flap (approximately 5 × 3 mm) was fashioned. AS-AW6 A-stream shunt model (MICROT Inc.) (preloaded with a 7-0 nylon intraluminal ripcord) was inserted into the anterior chamber through a 30-gauge needle tract. The wing plate was secured to the sclera using 10-0 nylon, and the scleral flap was fashioned to cover the tube and wing plate to reduce exposure risk. For subsequent ripcord removal, the ripcord was externalized as a small conjunctival loop and fixed to the sclera with 10-0 nylon. The conjunctiva and Tenon capsule were closed watertight with 10-0 nylon.

Postoperative management

Postoperative examinations were scheduled at postoperative day 1, week 1, weeks 2-3, and months 1, 2, 3, and 6 when available. IOP was measured using Goldmann applanation tonometry at each visit, and slit-lamp evaluation included assessment for anterior chamber reaction, hyphema, bleb morphology, and device-related complications.

Ripcord removal

Ripcord removal was performed at the physician’s discretion based on postoperative IOP and bleb appearance. In eyes undergoing ripcord removal, IOP was measured approximately 30 minutes after removal. In general, removal was considered when postoperative IOP exceeded the target range (≥17 mmHg) or when reduced filtration was suspected, such as decreased bleb height, encapsulation, or increased vascularity. For the purpose of analysis, early ripcord removal was operationally defined as removal performed within 4 weeks after surgery. This cutoff was chosen to reflect routine clinical practice, as the first postoperative month generally represents the early healing phase during which wound stabilization and inflammatory responses are most active [10]. Ripcord removal beyond 4 weeks was classified as late removal, reflecting a more stable postoperative period in which IOP trends and bleb morphology can be more reliably assessed [11]. This time-based categorization was intended to facilitate clinically interpretable subgroup analysis rather than to imply a fixed or protocol-driven removal strategy.

Postoperative interventions

Postoperative interventions, including bleb needling and subconjunctival 5-fluorouracil injections, were performed at the physician’s discretion when IOP remained above the target range (≥17 mmHg) despite escalation of topical therapy and when bleb findings suggested reduced filtration (e.g., flattening, encapsulation, or increased vascularity). Bleb needling with adjunctive 5-fluorouracil was considered for suspected bleb encapsulation or focal scarring with inadequate IOP control, whereas 5-fluorouracil injection alone was used when early subconjunctival fibrosis was suspected without a focal encapsulated bleb requiring needling.

Data collection

Baseline variables included age, sex, laterality, NVG etiology, systemic comorbidities (hypertension and diabetes mellitus), prior vitrectomy, preoperative PRP and intravitreal anti-VEGF history, prior glaucoma surgery, prior cataract surgery, and whether combined surgery was performed. Preoperative glaucoma severity parameters included Humphrey visual field indices (visual field index and mean deviation) and peripapillary retinal nerve fiber layer thickness and cup to disc ratio obtained using Cirrus HD-OCT 5000 (Carl Zeiss Meditec). Best-corrected visual acuity was analyzed in logMAR units. Preoperative decision IOP and the number of IOP-lowering medications were recorded.

Outcome measures and definitions

The primary outcome was time-point surgical success through 6 months. Complete success was defined as an IOP of 6 to 18 mmHg with ≥20% reduction from the preoperative decision IOP, without glaucoma medications or additional glaucoma surgery. Qualified success was defined as meeting the same IOP and reduction criteria with or without glaucoma medications, and without additional glaucoma surgery [9,12,13]. Secondary outcomes included longitudinal IOP and medication burden, ripcord removal timing, postoperative interventions (bleb needling and 5-fluorouracil injections), reoperation, and postoperative complications through 6 months.

Statistical analysis

Continuous variables are presented as mean ± standard deviation and categorical variables as counts and percentages. Changes in IOP and medication burden from baseline to each postoperative time point were assessed using paired t-tests or Wilcoxon signed-rank tests depending on distribution. Success rates (complete and qualified) were calculated at each prespecified visit (months 1, 2, 3, and 6). Statistical analyses were performed using IBM SPSS ver. 29 (IBM Corp.), and p-values <0.05 were considered statistically significant.

Results

Baseline characteristics

A total of 35 eyes with NVG that underwent A-stream shunt implantation were included. The mean age was 65.1 ± 10.1 years, and 25 patients (71.4%) were male. Five eyes (14.3%) had a history of prior glaucoma surgery, including XEN45 Gel Stent (Allergan, AbbVie Inc.) implantation in three eyes, trabeculectomy in one eye, and AGV implantation in one eye (Table 1). The most common NVG etiology was proliferative diabetic retinopathy (26 eyes, 74.3%), followed by central retinal vein occlusion (6 eyes, 17.1%), ocular ischemic syndrome (2 eyes, 5.7%), and central retinal artery occlusion (1 eye, 2.9%) (Table 1). Mean preoperative IOP was 37.0 ± 13.2 mmHg on 2.6 ± 1.2 IOP-lowering medications (Table 1).

Postoperative IOP and medication outcomes

IOP decreased markedly after surgery, from 37.0 ± 13.2 mmHg preoperatively to 10.1 ± 6.9 mmHg on postoperative day 1 and remained in the mid-teens through 6 months (15.7 ± 6.3 mmHg at month 6) (Table 2, Fig. 1A). Among eyes that underwent ripcord removal, the mean IOP at the time of ripcord removal was 21.2 ± 5.4 mmHg (Table 2). Glaucoma medication use decreased substantially from baseline and remained low through follow-up (0.1 ± 0.3 on postoperative day 1 and 0.7 ± 0.9 at month 6) (Table 3, Fig. 1B). At the 6-month follow-up visit, the mean postoperative best-corrected visual acuity was 1.45 ± 1.17 logMAR.

Ripcord removal and postoperative interventions

Ripcord removal was performed in 28 eyes (80.0%); 14 eyes (40.0%) underwent early removal (≤4 weeks) and 14 eyes (40.0%) underwent late removal (>4 weeks), with a mean removal time of 6.6 ± 4.7 weeks (Table 4, Fig. 2). In the 28 eyes that underwent ripcord removal, postremoval IOP outcomes were comparable between the early and late groups (Table 5). Fig. 3 illustrates representative postoperative changes in bleb morphology following A-stream shunt implantation in a patient with NVG who underwent ripcord removal at postoperative week 4. Prior PRP and intravitreal anti-VEGF history were not significantly associated with early (≤4 weeks) versus late (>4 weeks) ripcord removal (PRP: 50.0% vs. 57.1%, p = 0.705; anti-VEGF: 57.1% vs. 64.3%, p = 0.699). Postoperative interventions included bleb needling in five eyes (14.3%) and 5-fluorouracil injections in nine eyes (25.7%) with a mean of 1.33 ± 0.71 injections per treated eye, and one eye (2.9%) required reoperation (Table 4). Postoperative hyphema occurred in five eyes (14.3%) and was managed conservatively (Table 4). Reoperation was performed because IOP remained uncontrolled despite maximally tolerated medical therapy, and the eye subsequently underwent AGV implantation.

Surgical success

From postoperative months 1 to 6, complete success was achieved in 25 eyes (71.4%) at month 1 and 20 eyes (57.1%) at month 6, while qualified success was achieved in 26 eyes (74.3%) at month 1 and remained favorable at month 6 (30 eyes, 85.7%) (Fig. 4).

Discussion

In this retrospective single-center cohort of NVG eyes undergoing A-stream shunt implantation, we observed substantial reductions in IOP and glaucoma medication burden through 6 months, with favorable short-term surgical outcomes. A notable finding was the frequent and relatively early use of ripcord removal in NVG: among eyes that underwent removal, the mean timing was about 6 to 7 weeks and 40.0% underwent removal within 4 weeks, suggesting that early postoperative IOP dynamics and bleb function frequently required stepwise augmentation of filtration in this population.
Clinical results for other glaucoma surgical methods have already been reported in the NVG patient population. Trabeculectomy remains a widely used filtering procedure; however, outcomes in NVG can be compromised by postoperative hyphema, inflammation, and aggressive subconjunctival fibrosis, leading to higher rates of bleb failure and postoperative interventions [14-16]. In a retrospective cohort of 101 NVG eyes undergoing trabeculectomy with mitomycin C, the cumulative probability of success was 62.6% at 1 year and 58.2% at 2 years [17]. Glaucoma drainage devices such as the AGV are commonly selected for NVG, as they may be less dependent on bleb maturation and more tolerant of the inflammatory/hemorrhagic milieu [6,18]. In comparative studies of NVG, the cumulative probability of success after AGV implantation was 70% at 1 year and 60% at 2 years, with broadly similar cumulative success to trabeculectomy [6,18,19].
In this context, A-stream implantation achieved a qualified success rate of 85.7% and a complete success rate of 57.1% at 6 months under our stringent success criteria (IOP 6-18 mmHg with ≥20% reduction from the preoperative decision IOP). These short-term outcomes appear comparable to those reported for established surgical options for NVG, such as trabeculectomy with mitomycin C and AGV implantation, although direct comparisons are limited by differences in success definitions and follow-up duration. Importantly, A-stream offers postoperative outflow titration via an adjustable intraluminal ripcord mechanism.
The tendency toward earlier ripcord removal in NVG in our cohort may reflect a common clinical scenario: early postoperative IOP spikes or signs of reduced filtration (e.g., early encapsulation or increased vascularity) prompting surgeons to increase aqueous egress sooner. This pattern contrasts with previously reported A-stream outcomes in predominantly non-NVG eyes, where ripcord removal was commonly performed around postoperative month 2 and was followed by additional IOP reduction after removal [9]. Taken together, these findings support the concept that the ripcord functions as a practical, stepwise postoperative “titration” tool—particularly relevant in NVG where the early postoperative course can be volatile. Early ripcord removal may theoretically increase the risk of postoperative hypotony by augmenting aqueous outflow before wound healing stabilizes [9]. However, hypotony maculopathy was not observed in our cohort, and ripcord removal was performed in a clinically guided manner based on IOP and bleb findings to mitigate excessive filtration.
Medication-free control (complete success) may be less achievable in NVG because persistent retinal ischemia and ongoing inflammatory drive can sustain elevated outflow resistance, necessitating adjunctive topical therapy even after successful surgery [6]. Therefore, the favorable qualified success observed in this study may be clinically meaningful, suggesting that A-stream implantation could serve as a reasonable alternative option for selected NVG eyes, particularly when the goal is reliable IOP control with an acceptable medication burden rather than strict medication-free success.
This study has several limitations, including its retrospective design, the absence of a control group, and the relatively limited sample size. Additionally, although the follow-up period was sufficient to evaluate mid-term outcomes, longer follow-up is required to assess long-term tube survival and late postoperative complications. Nevertheless, given the rarity and severity of NVG, conducting randomized or comparative surgical trials remains challenging, and real-world observational data remain clinically valuable.
In conclusion, A-stream shunt implantation provided substantial short-term IOP lowering with low medication requirements and favorable qualified success through 6 months in NVG eyes. Ripcord removal was frequently required and tended to occur early, supporting the role of stepwise outflow titration as a practical postoperative strategy in NVG.

Notes

Conflicts of Interest

None.

Acknowledgements

None.

Funding

None.

References

1. Verma S, Midha N, Udenia H, Dada T. Updates in the treatment of neovascular glaucoma: From conventional approaches to novel therapies. Indian J Ophthalmol 2025;73:1412-21.
crossref pmid pmc
2. Dumbraveanu L, Cusnir V, Bobescu D. A review of neovascular glaucoma: etiopathogenesis and treatment. Rom J Ophthalmol 2021;65:315-29.
pmid pmc
3. Calugaru D, Calugaru M. Etiology, pathogenesis, and diagnosis of neovascular glaucoma. Int J Ophthalmol 2022;15:1005-10.
crossref pmid pmc
4. Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009;24:113-21.
crossref pmid
5. Olmos LC, Sayed MS, Moraczewski AL, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye (Lond) 2016;30:463-72.
pmid
6. Shen CC, Salim S, Du H, Netland PA. Trabeculectomy versus Ahmed glaucoma valve implantation in neovascular glaucoma. Clin Ophthalmol 2011;5:281-6.
pmid pmc
7. He Y, Tian Y, Song W, et al. Clinical efficacy analysis of Ahmed glaucoma valve implantation in neovascular glaucoma and influencing factors: a STROBE-compliant article. Medicine (Baltimore) 2017;96:e8350.
pmid pmc
8. Netland PA. The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis). Trans Am Ophthalmol Soc 2009;107:325-42.
pmid pmc
9. Park HM, Lee EJ, Han JC, et al. Short-term efficacy and safety of A-stream glaucoma shunt: a 6-month study. Eye (Lond) 2025;39:1584-91.
crossref pmid pmc pdf
10. Masoumpour MB, Nowroozzadeh MH, Razeghinejad MR. Current and future techniques in wound healing modulation after glaucoma filtering surgeries. Open Ophthalmol J 2016;10:68-85.
crossref pmid pmc pdf
11. Sun Y, Zhu J, Guo J, et al. Clinical value of anterior segment optical coherence tomography-assisted Wuerzburg bleb classification system for bleb assessment following trabeculectomy. Exp Ther Med 2023;25:280.
crossref pmid pmc
12. Szigiato AA, Touma S, Jabbour S, et al. Efficacy of ab-interno gelatin microstent implantation in primary and refractory glaucoma. Can J Ophthalmol 2023;58:328-37.
crossref pmid
13. Stallworth JY, O’Brien KS, Han Y, Oatts JT. Efficacy of Ahmed and Baerveldt glaucoma drainage device implantation in the pediatric population: a systematic review and meta-analysis. Surv Ophthalmol 2023;68:578-90.
crossref pmid pmc
14. Mandal AK, Majji AB, Mandal SP, et al. Mitomycin-C-augmented trabeculectomy for neovascular glaucoma: a preliminary report. Indian J Ophthalmol 2002;50:287-93.
pmid
15. Hyung SM, Kim SK. Mid-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients. Korean J Ophthalmol 2001;15:98-106.
crossref pmid
16. Nakatake S, Yoshida S, Nakao S, et al. Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis. BMC Ophthalmol 2014;14:55.
crossref pmid pmc pdf
17. Takihara Y, Inatani M, Fukushima M, et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol 2009;147:912-8.
crossref pmid
18. Kang YK, Shin JP, Kim DW. Long-term surgical outcomes of Ahmed valve implantation in refractory glaucoma according to the type of glaucoma. BMC Ophthalmol 2022;22:270.
crossref pmid pmc pdf
19. Yalvac IS, Eksioglu U, Satana B, Duman S. Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye (Lond) 2007;21:65-70.
crossref pmid pdf

Fig. 1
Intraocular pressure (IOP) and glaucoma medication reduction following A-stream shunt implantation in neovascular glaucoma. (A) Box-and-whisker plot showing IOP measured preoperatively and at postoperative day 1, week 1, weeks 2-3, and months 1, 2, 3, and 6. (B) Box-and-whisker plot illustrating the mean number of glaucoma medications used preoperatively and at postoperative day 1, week 1, weeks 2-3, and months 1, 2, 3, and 6.
kjo-2026-0010f1.jpg
Fig. 2
Distribution of postoperative ripcord removal timing after A-stream shunt implantation in eyes with neovascular glaucoma. Bars indicate the number of eyes in each time interval. Ripcord removal timing was summarized as 1-4 weeks and 2-5 months postoperatively; eyes without ripcord removal were excluded.
kjo-2026-0010f2.jpg
Fig. 3
Representative case demonstrating postoperative bleb stabilization following A-stream shunt implantation in neovascular glaucoma. A 64-year-old female patient with neovascular glaucoma underwent A-stream shunt surgery. On postoperative day 1, the A-stream tube with an intraluminal ripcord was visible at the superior angle, with residual iris neovascularization noted posteriorly. Subconjunctival hemorrhage was present; however, the bleb appeared diffuse, and the ripcord formed an external conjunctival loop. By postoperative week 1, the subconjunctival hemorrhage had largely resolved. At postoperative month 1, intraocular pressure increased to the high-teen range, and the ripcord was removed. By postoperative month 6, conjunctival vascularity over the bleb surface had markedly decreased, demonstrating progressive bleb stabilization.
kjo-2026-0010f3.jpg
Fig. 4
Surgical success following A-stream shunt implantation in neovascular glaucoma. Line plot showing complete and qualified success rates at postoperative months 1, 2, 3, and 6. Complete success was defined as an intraocular pressure (IOP) of 6-18 mmHg with ≥20% reduction from the preoperative decision IOP, without glaucoma medications or additional glaucoma surgery. Qualified success was defined as meeting the same IOP and reduction criteria with or without medications, and without additional glaucoma surgery.
kjo-2026-0010f4.jpg
Table 1
Baseline demographic and clinical characteristics of the study eyes
Characteristic All eyes (n = 35)
Age (yr) 65.1 ± 10.1
Male sex 25 (71.4)
Preoperative VA (logMAR) 1.44 ± 1.18
Hypertension 18 (51.4)
Diabetes mellitus 34 (97.1)
Prior cataract surgery 24 (68.6)
Prior vitrectomy surgery 6 (17.1)
Prior glaucoma surgery 5 (14.3)
 XEN gel stent 3 (8.6)
 Trabeculectomy 1 (2.9)
 Ahmed glaucoma valve 1 (2.9)
Prior PRP 20 (57.1)
Prior anti-VEGF injection 23 (65.7)
HVF VFI (%) 32.5 ± 33.3
HVF MD (dB) −22.6 ± 9.2
RNFL thickness (μm) 57.8 ± 19.7
No. of IOP-lowering medications 2.6 ± 1.2
Preoperative IOP (mmHg) 37.0 ± 13.2
NVG type
 PDR 26 (74.3)
 CRVO 6 (17.1)
 OIS 2 (5.7)
 CRAO 1 (2.9)

Values are presented as mean ± standard deviation or number (%). VA = visual acuity; PRP = panretinal photocoagulation; VEGF = vascular endothelial growth factor; HVF = Humphrey visual field; VFI = visual field index; MD = mean deviation; RNFL = retinal nerve fiber layer; IOP = intraocular pressure; NVG = neovascular glaucoma; PDR = proliferative diabetic retinopathy; CRVO = central retinal vein occlusion; OIS = ocular ischemic syndrome; CRAO = central retinal artery occlusion.

Table 2
Postoperative IOP outcomes following A-stream shunt implantation in neovascular glaucoma
Follow-up IOP (mmHg)
Day 1 10.1 ± 6.9
Week 1 10.4 ± 5.2
Week 2-3 12.7 ± 5.5
Month 1 15.3 ± 5.7
Month 2 16.9 ± 7.8
Month 3 13.2 ± 5.2
Month 6 15.7 ± 6.3
IOP at ripcord removal 21.2 ± 5.4

Values are presented as mean ± standard deviation.

IOP = intraocular pressure.

Table 3
Postoperative glaucoma medication burden following A-stream shunt implantation in neovascular glaucoma
Follow-up No. of glaucoma medications
Day 1 0.1 ± 0.3
Week 1 0.1 ± 0.3
Week 2-3 0.1 ± 0.3
Month 1 0.1 ± 0.4
Month 2 0.3 ± 0.6
Month 3 0.6 ± 0.8
Month 6 0.7 ± 0.9

Values are presented as mean ± standard deviation.

Table 4
Postoperative outcomes and interventions following A-stream shunt implantation in neovascular glaucoma
Variable All eyes (n = 35)
Final postoperative VA (logMAR) 1.45 ± 1.17
Needling 5 (14.3)
5-FU injection 9 (25.7)
5-FU injections per treated eye 1.33 ± 0.71
Reoperation 1 (2.9)
Postoperative hyphema 5 (14.3)
Ripcord removal 28 (80.0)
 Early removal (≤4 wk) 14 (40.0)
 Late removal (>4 wk) 14 (40.0)
No ripcord removal 7 (20.0)
Ripcord removal time (wk) 6.6 ± 4.7

Values are presented as mean ± standard deviation or number (%).

VA=visualacuity;5-FU=5-fluorouracil

Table 5
Intraocular pressure at the time of ripcord removal in early and late removal groups
Time point Early removal (≤4 wk) (n = 14) Late removal (>4 wk) (n = 14) p-value*
Immediately after ripcord removal (mmHg)† 11.4 ± 2.5 10.0 ± 3.3 0.23
At 1 week after ripcord removal (mmHg) 12.8 ± 5.7 11.1 ± 4.2 0.39

Values are presented as mean ± standard deviation.

* Welch t-test;

† ‘Immediately after ripcord removal’ indicates intraocular pressure measured approximately 30 minutes after removal.



ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#1001, Jeokseon Hyundai BD
130, Sajik-ro, Jongno-gu, Seoul 03170, Korea
Tel: +82-2-2266-7397    Fax: +82-2-2277-5194    E-mail: kos@ijpnc.com                

Copyright © 2026 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next